Plavix is one of the best selling drugs in the world, with about $9 billion dollars in sales in 2009. After Fitzpatrick attorneys enforced the Plavix patent in litigation on behalf of plaintiff clients Sanofi-Aventis and Bristol-Myers Squibb, defendant Apotex, Inc. filed a request for ex parte reexamination in the U.S. Patent and Trademark Office in June 2009. Fitzpatrick attorneys Robert Baechtold, John Murnane, Michael Furrow and Alicia Russo opposed Apotex’s efforts to invalidate the patent; and the Patent Office confirmed the patentability of the claims in March 2010. The next month, Apotex filed a second request for reexamination seeking to invalidate the patent, which Fitzpatrick also opposed. The Patent Office denied that request in June 2010 and confirmed its decision in an October 2010 ruling.
For more information, please click here.